Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)

Overview of attention for article published in Frontiers in oncology, September 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,761 followers.

RT @FrontOncology: New research: Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicen…

09 Sep 2023

Reply Repost Favourite

New research: Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001): Background Anlotinib showed encouraging anti-tumor activity in metastatic colorectal… #oncology http

09 Sep 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.